Helius Medical Technologies (HSDT)
(Delayed Data from NSDQ)
$0.55 USD
+0.02 (3.62%)
Updated Oct 4, 2024 03:55 PM ET
After-Market: $0.52 -0.03 (-5.45%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.55 USD
+0.02 (3.62%)
Updated Oct 4, 2024 03:55 PM ET
After-Market: $0.52 -0.03 (-5.45%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 31.37% and 3.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 40% and 1.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 1249.93% Upside in Helius Medical Technologies, Inc. (HSDT): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Helius Medical Technologies, Inc. (HSDT) points to a 1249.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in Helius Medical Technologies, Inc. (HSDT)? Wall Street Analysts Think 1183.3%
by Zacks Equity Research
The consensus price target hints at an 1183.3% upside potential for Helius Medical Technologies, Inc. (HSDT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 45.45% and 50.59%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 19.64% and 2.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences (EW) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.54% and 1.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of -10.26% and 1.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 18.18% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Winning Stocks Backed by the Overlooked Rising P/E Trick
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).
Helius Medical Technologies, Inc. (HSDT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -16.67% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 8.70% and 2.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Helius Medical Technologies, Inc. (HSDT) a New Buy Stock
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Helius Medical Technologies, Inc. (HSDT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -14.86% and 37.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for August 20th
by Zacks Equity Research
ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.
Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -68.63% and -21.11%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Helius Medical Technologies, Inc. (HSDT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Helius Medical Technologies, Inc. (HSDT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 33.33% and 33.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of 0.00% and -50.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?